Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2021 Filed Oct 4, 2021 22:11 UTC |
Vieser JaimeDirector
|
PurchaseCommon Stock | 100,000 | $1.91 | $191,000.00 |
DisclosureSEC source: 0001209191-21-059131 · doc4.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,321 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:25 UTC |
Hagen HeidiDirector
|
PurchaseCommon Stock | 23,770 | $1.76 | $41,835.20 |
DisclosureSEC source: 0001209191-21-054829 · doc4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,889 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:22 UTC |
Postma Robert WDirector
|
PurchaseCommon Stock | 54,492 | $1.73 | $94,271.16 |
DisclosureSEC source: 0001209191-21-054825 · doc4.xml · nonDerivative · entry 2 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,250,000 F2 · ownership.nature: The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:22 UTC |
Postma Robert WDirector
|
PurchaseCommon Stock | 20,508 | $1.73 | $35,478.84 |
DisclosureSEC source: 0001209191-21-054825 · doc4.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201,870 F1 · balance_after: Includes 946,970 shares of common stock underlying the Units. The Reporting Person purchased 946,970 units of the Issuer (the "Units") for $2.64 per Unit in a private placement transaction with the Issuer. Each Unit consists of one share of common stock and a warrant to acquire one share of common stock. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:23 UTC |
Weis HolgerDirector
|
PurchaseCommon Stock | 50,000 | $1.83 | $91,500.00 |
DisclosureSEC source: 0001209191-21-054828 · doc4.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,167 F1 · balance_after: Includes 30,000 shares held in a joint account by the Reporting Person and his spouse. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:21 UTC |
Huang JamesDirector
|
PurchaseCommon Stock | 100,000 | $1.71 | $171,000.00 |
DisclosureSEC source: 0001209191-21-054824 · doc4.xml · nonDerivative · entry 1 Huang James · CIK 0001573160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,333 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:42 UTC |
Boyle Kevin S. Sr.Director · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,625,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001209191-21-054089 · doc4.xml · derivative · entry 2 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625,000 Underlying: Common Stock · 2,625,000 shares Expires 2031-08-29 F2 · derivative.exercise_date: One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three month after 8/30/2021, subject to the Reporting Person's continued service through each such date. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 20:42 UTC |
Boyle Kevin S. Sr.Director · Chief Executive Officer
|
GrantCommon Stock | 875,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054089 · doc4.xml · nonDerivative · entry 1 Boyle Kevin S. Sr. · CIK 0001880600 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 F1 · shares: One-fourth of the shares vest on each of August 30, 2022, August 30, 2023, August 30, 2024 and August 30, 2025, subject to the Reporting Person's continued service through each such date. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:55 UTC |
Baffa RaffaeleChief Medical Officer
|
GrantCommon Stock | 80,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-034027 · doc4.xml · nonDerivative · entry 1 Baffa Raffaele · CIK 0001853684 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,645 F1 · shares: One-third of the shares vest on each of September 1, 2021, February 1, 2022 and May 1, 2022, subject to the Reporting Person's continued service through each such date. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:30 UTC |
Buck JillEVP, GM Gene Therapy
|
GrantEmployee Stock Option (right to buy) · Derivative | 236,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-018632 · doc4.xml · derivative · entry 2 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,250 Underlying: Common Stock · 236,250 shares Expires 2031-03-04 F2 · derivative.exercise_date: 1/16th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:30 UTC |
Buck JillEVP, GM Gene Therapy
|
GrantCommon Stock | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018632 · doc4.xml · nonDerivative · entry 1 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,016 F1 · shares: 7,875 shares shall vest on each of 12/31/2021, 12/31/2022, 12/31/2023 and 12/31/2024. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:29 UTC |
Hadfield RobertChief Legal Officer and Sec.
|
GrantEmployee Stock Option (right to buy) · Derivative | 326,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-018630 · doc4.xml · derivative · entry 2 Hadfield Robert · CIK 0001630687 · Chief Legal Officer and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,250 Underlying: Common Stock · 326,250 shares Expires 2031-03-04 F2 · derivative.exercise_date: 1/16th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:29 UTC |
Hadfield RobertChief Legal Officer and Sec.
|
GrantCommon Stock | 43,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018630 · doc4.xml · nonDerivative · entry 1 Hadfield Robert · CIK 0001630687 · Chief Legal Officer and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,819 F1 · shares: 10,875 shares shall vest on each of 12/31/2021, 12/31/2022, 12/31/2023 and 12/31/2024. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:28 UTC |
Hagen HeidiDirector · Interim CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 675,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-018629 · doc4.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2031-03-04 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal monthly installments commencing one month after 3/4/2021. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:28 UTC |
Hagen HeidiDirector · Interim CEO
|
GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018629 · doc4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,119 F1 · shares: The shares will fully vest on 3/4/2022. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:26 UTC |
De Groot EleanorEVP, GM Cell Therapy
|
GrantEmployee Stock Option (right to buy) · Derivative | 381,188 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-018628 · doc4.xml · derivative · entry 2 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,188 Underlying: Common Stock · 381,188 shares Expires 2031-03-04 F2 · derivative.exercise_date: 1/16th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:26 UTC |
De Groot EleanorEVP, GM Cell Therapy
|
GrantCommon Stock | 50,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018628 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,238 F1 · shares: 12,707 shares shall vest on 12/31/2021 and 12,706 shares shall vest on each of 12/31/2022, 12/31/2023 and 12/31/2024. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:27 UTC |
Weis HolgerDirector
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030746 · doc4.xml · derivative · entry 7 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-03 F4 · derivative.exercise_date: 1/36th of the shares underlying this option will vest in equal monthly installments commencing one month after 12/15/2020. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:27 UTC |
Weis HolgerDirector
|
GrantStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030746 · doc4.xml · derivative · entry 6 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2031-03-03 F3 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:27 UTC |
Weis HolgerDirector
|
GrantCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030746 · doc4.xml · nonDerivative · entry 1 Weis Holger · CIK 0001846984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,167 F1 · shares: The shares will vest on 5/19/2021. F2 · balance_after: Includes 30,000 shares held in a joint account by the Reporting Person and his spouse. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:26 UTC |
Vieser JaimeDirector
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030745 · doc4.xml · derivative · entry 7 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-03 F3 · derivative.exercise_date: 1/36th of the shares underlying this option will vest in equal monthly installments commencing one month after 12/15/2020. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:26 UTC |
Vieser JaimeDirector
|
GrantStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030745 · doc4.xml · derivative · entry 6 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2031-03-03 F2 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:26 UTC |
Vieser JaimeDirector
|
GrantCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030745 · doc4.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,321 F1 · shares: The shares will vest on 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:25 UTC |
Thistle MaryDirector
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030743 · doc4.xml · derivative · entry 3 Thistle Mary · CIK 0001317917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-03 F3 · derivative.exercise_date: 1/36th of the shares underlying this option will vest in equal monthly installments commencing one month after 11/15/2020. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:25 UTC |
Thistle MaryDirector
|
GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030743 · doc4.xml · derivative · entry 2 Thistle Mary · CIK 0001317917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2031-03-03 F2 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:25 UTC |
Thistle MaryDirector
|
GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030743 · doc4.xml · nonDerivative · entry 1 Thistle Mary · CIK 0001317917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The shares will vest on 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:24 UTC |
Postma Robert WDirector
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030742 · doc4.xml · derivative · entry 5 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-03 F5 · derivative.exercise_date: 1/36th of the shares underlying this option will vest in equal monthly installments commencing one month period after 12/15/2020. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:24 UTC |
Postma Robert WDirector
|
GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030742 · doc4.xml · derivative · entry 4 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2031-03-03 F4 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:24 UTC |
Postma Robert WDirector
|
GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030742 · doc4.xml · nonDerivative · entry 1 Postma Robert W · CIK 0001827847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,181,362 F1 · shares: The shares will vest on 5/19/2021. F2 · balance_after: Includes 946,970 shares of common stock underlying the Units. The Reporting Person purchased 946,970 units of the Issuer (the "Units") for $2.64 per Unit in a private placement transaction with the Issuer. Each Unit consists of one share of common stock and a warrant to acquire one share of common stock. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:22 UTC |
Huang JamesDirector
|
GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030740 · doc4.xml · derivative · entry 2 Huang James · CIK 0001573160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2031-03-03 F2 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:22 UTC |
Huang JamesDirector
|
GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030740 · doc4.xml · nonDerivative · entry 1 Huang James · CIK 0001573160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 F1 · shares: The shares will vest on 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:21 UTC |
BUCHI J KEVINDirector
|
GrantStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030738 · doc4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2031-03-03 F2 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:21 UTC |
BUCHI J KEVINDirector
|
GrantCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030738 · doc4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 F1 · shares: The shares will vest on 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:20 UTC |
Bowden ChristopherDirector
|
GrantStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030737 · doc4.xml · derivative · entry 2 Bowden Christopher · CIK 0001608601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2031-03-03 F2 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:20 UTC |
Bowden ChristopherDirector
|
GrantCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030737 · doc4.xml · nonDerivative · entry 1 Bowden Christopher · CIK 0001608601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 F1 · shares: The shares will vest on 5/19/2021. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:35 UTC |
Buck JillEVP, GM Gene Therapy
|
SaleCommon Stock | 27,894 | $3.12 | $87,029.28 |
DisclosureSEC source: 0001209191-21-003245 · doc4.xml · nonDerivative · entry 1 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,516 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.035 to $3.205, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:34 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
SaleCommon Stock | 18,020 | $3.09 | $55,681.80 |
DisclosureSEC source: 0001209191-21-003244 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,965 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:33 UTC |
Hadfield RobertGeneral Counsel and Secretary
|
SaleCommon Stock | 26,500 | $3.12 | $82,680.00 |
DisclosureSEC source: 0001209191-21-003242 · doc4.xml · nonDerivative · entry 1 Hadfield Robert · CIK 0001630687 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,319 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.035 to $3.195, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:03 UTC |
De Groot EleanorEVP, GM Cell Therapy
|
SaleCommon Stock | 21,620 | $2.72 | $58,806.40 |
DisclosureSEC source: 0001209191-21-002174 · doc4.xml · nonDerivative · entry 1 De Groot Eleanor · CIK 0001780420 · EVP, GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,413 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:02 UTC |
Cooper Laurence James NeilDirector · President and CEO
|
SaleCommon Stock | 105,693 | $2.71 | $286,428.03 |
DisclosureSEC source: 0001209191-21-002171 · doc4.xml · nonDerivative · entry 1 Cooper Laurence James Neil · CIK 0001641506 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,799,280 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 20:55 UTC |
BUCHI J KEVINDirector
|
GrantStock Option (right to buy) · Derivative | 146,190 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001209191-20-054667 · doc4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,190 Underlying: Common Stock · 146,190 shares Expires 2030-10-08 F1 · derivative.exercise_date: The shares underlying this option will vest on September 21, 2022, subject to the Reporting Person's continuous service to the Issuer through such date; vesting of all shares subject to the option shall vest upon a change of control. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 21:03 UTC |
Huang JamesDirector
|
GrantStock Option (right to buy) · Derivative | 119,178 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001209191-20-043323 · doc4.xml · derivative · entry 1 Huang James · CIK 0001573160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,178 Underlying: Common Stock · 119,178 shares Expires 2030-07-20 F1 · derivative.exercise_date: The shares underlying this option will vest on July 20, 2022. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:44 UTC |
Buck JillEVP, GM Gene Therapy
|
GrantEmployee Stock Option (right to buy) · Derivative | 82,600 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005778 · doc4.xml · derivative · entry 2 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,600 Underlying: Common Stock · 82,600 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:44 UTC |
Buck JillEVP, GM Gene Therapy
|
GrantCommon Stock | 53,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005778 · doc4.xml · nonDerivative · entry 1 Buck Jill · CIK 0001780426 · EVP, GM Gene Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,410 F1 · shares: 17,900 shares shall vest on each of 12/31/2020, 12/31/2021 and 12/31/2022. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:51 UTC |
MAUNEY DAVID M MDPresident
|
GrantEmployee Stock Option (right to buy) · Derivative | 123,900 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005787 · doc4.xml · derivative · entry 2 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,900 Underlying: Common Stock · 123,900 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:51 UTC |
MAUNEY DAVID M MDPresident
|
GrantCommon Stock | 80,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005787 · doc4.xml · nonDerivative · entry 1 MAUNEY DAVID M MD · CIK 0001305832 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,778 F1 · shares: 26,834 shares shall vest on 12/31/2020 and 26,833 shares shall vest on each of 12/31/2021 and 12/31/2022. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:52 UTC |
Shukla SathEVP, Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 123,900 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005789 · doc4.xml · derivative · entry 2 Shukla Sath · CIK 0001782817 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,900 Underlying: Common Stock · 123,900 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:52 UTC |
Shukla SathEVP, Chief Financial Officer
|
GrantCommon Stock | 80,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005789 · doc4.xml · nonDerivative · entry 1 Shukla Sath · CIK 0001782817 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,500 F1 · shares: 26,834 shares shall vest on 12/31/2020 and 26,833 shares shall vest on each of 12/31/2021 and 12/31/2022. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:50 UTC |
Lafond Kevin GSVP, Treasurer & CAO
|
GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005785 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,985 F1 · shares: 6,000 shares shall vest on each of 12/31/2020, 12/31/2021 and 12/31/2022. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:48 UTC |
Hadfield RobertGeneral Counsel and Secretary
|
GrantEmployee Stock Option (right to buy) · Derivative | 90,800 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-20-005783 · doc4.xml · derivative · entry 2 Hadfield Robert · CIK 0001630687 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,800 Underlying: Common Stock · 90,800 shares Expires 2030-01-29 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.